Contatti:

cell: +39 329 0364389​

info@biomole.it

logo
logo

biomole@ALL RIGHT RESERVED 2019

cookie Policy | Privacy policy

201904151249411

IFNsig.type II-RT-PCR real time real time

Quantification assay of type II interferonopathies          cod. BM-013

Principle of the test: Quantitative analysis of ISGs mRNA expression

Technology: Relative Quantitative Real Time PCR

Genes Target: IFN-γ, CXCL9, CXCL10, and IDO1

Specimen: cDNA

Results within: ΔΔCt method

Reporting Units: Arbitrary Units (AU)

Number of tests: 25 tests BM-013

Kit storage: -20°C

Necessary equipment: Thermocycler, 7500 Real Time PCR System

Status: Ready to use

IFNsig.type II-RT-PCR real time real time  cod. BM-013

 

Quantification assay of type II interferonopathies

 

·      IFNsig.type II-RT-PCR real time Quantification complete kit 25 tests BM-013

 

Type II IFN, known as IFN-γ, while sharing a similar nomenclature to type I IFN, signals through a different receptor and has effects that are independent from type I IFN. As a part of the innate immune response, they are predominantly produced by natural killer cells during infection25. IFN-γ is a key cytokine produced by activated T cells, as well as natural killer (NK) and NK T cells, in the tumor microenvironment, and it plays an important role in coordinating this process. In addition, IFN-γ can upregulate expression of other key immune suppressive molecules such as IDO1 within the tumor microenvironment26. Lee and colleagues shown that IFN-γ can upregulate expression of other key immune suppressive molecule such as CXCL9 and CXCL10 and named its as IFN-γ signatures or IFN signature type II25. Recently, Imgenberg-Kreuz and colleagues present whole transcriptome profiling in B cells from patients with autoantibody-positive primary Sjogren’s syndrome (pSS) identifying extensive differences in expression patterns compared with controls, including a prominent type I and type II IFN signature27. This study adds to the current knowledge of the importance of B cells in pSS and as future therapeutic targets.

We developed a novel real-time qPCR assays able to amplified 4 ISGs: IFN-γ (Interferon gamma), CXCL9 (C-X-C motif chemokine ligand 9), CXCL10 (C-X-C motif chemokine ligand 10), and IDO1 (Indoleamine 2,3-dioxygenase 1). Relative quantification of target gene expression in patients was performed with the ΔΔCt method and the relative ISGs fold changes were determined. Results are expressed in corresponding arbitrary units (AU) User friendly and complete, the IFNsig. TypeII-RT-PCR real time Quantification kit is suitable for any laboratory.

 

Reference

1.      Lee AJ, Ashkar AA. The Dual Nature of Type I and Type II Interferons. Front Immunol. 2018 Sep 11;9:2061. doi: 10.3389/fimmu.2018.02061

2.      Spranger S, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116.

3.      Imgenberg-Kreuz J, Sandling JK, Björk A, Nordlund J, Kvarnström M, Eloranta ML, Rönnblom L, Wahren-Herlenius M, Syvänen AC, Nordmark G. Transcription profiling of peripheral B cells in antibody-positive primary Sjögren's syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature. Scand J Immunol. 2018 May;87(5):e12662. doi: 10.1111/sji.12662.